IMAXIO is an integrated biotech company operating in the vaccine and diagnostic fields.

In vaccine, IMAXIO focuses its research on carrier protein that may have adjuvant-like effects and commercializes a vaccine in the French market (Spirolept ^®).

In the diagnostic field, IMAXIO relies on several technology platforms specializing in genomics to develop innovative diagnostic tests centered on oncology and other therapeutic areas.

IMAXIO is a member of Lyonbiopôle, a pole of excellence in healthcare and of Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA), a structure of cancer research.